• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

术后同步放化疗与单纯术后放疗治疗伴淋巴管浸润的喉鳞状细胞癌患者:一项倾向评分匹配研究

Postoperative Concurrent Chemoradiotherapy versus Postoperative Radiotherapy Alone for Larynx Squamous Cell Carcinoma Patients with Lymphovascular Invasion: A Propensity Score Matching Study.

作者信息

Yu Shuting, Zhu Yingying, Shi Xiaohua, Hu Ke, Bai Chunmei, Diao Wenwen, Zhu Xiaoli, Gao Zhiqiang, Chen Xingming

机构信息

Department of Otolaryngology-Head and Neck Surgery, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, People's Republic of China.

Department of Pathology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, People's Republic of China.

出版信息

Cancer Manag Res. 2020 May 29;12:4063-4071. doi: 10.2147/CMAR.S250621. eCollection 2020.

DOI:10.2147/CMAR.S250621
PMID:32581580
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7269631/
Abstract

PURPOSE

To date, no guidelines have been proposed for the ideal treatment of postoperative larynx squamous cell carcinoma (LSCC) patients with lymphovascular invasion due to a lack of similar studies. The present study was conducted to compare the survival and toxicity in LSCC patients with lymphovascular invasion receiving either postoperative radiotherapy (PORT) or postoperative chemoradiotherapy (POCRT). The results can be applied for more appropriate treatment of these patients.

PATIENTS AND METHODS

Three hundred eighty-eight eligible LSCC patients with lymphovascular invasion were enrolled in this retrospective study. Survival and treatment-related toxicities were compared in the POCRT and PORT group using propensity score matching (PSM) methodology (1:1).

RESULTS

Five-year overall survival (OS), disease-specific survival (DSS), and recurrence-free survival (RFS) of all patients were 48.7%, 58.2%, and 56.0%, respectively. Significantly, higher RFS rates (P=0.040) were found in the POCRT group than the PORT group in the PSM cohort. In the multivariate analysis, higher OS, DSS, and RFS rates were observed in the POCRT group than the PORT group (P=0.049, 0.024, and 0.011 respectively). Patients in the POCRT group presented more acute toxicities than those in the PORT group such as hematological toxicities (25.0% vs 0.9%, P<0.001) and mucositis (35.0% vs 19.1%, P=0.002).

CONCLUSION

In the context of no ideal treatment for LSCC patients with lymphovascular invasion, the present study proposes POCRT as a preferable modality compared with PORT, as POCRT was associated with higher RFS rates. Higher RFS, DFS, and OS rates were also observed in the POCRT group in the multivariate analysis.

摘要

目的

迄今为止,由于缺乏类似研究,尚未有针对术后伴有淋巴管侵犯的喉鳞状细胞癌(LSCC)患者的理想治疗指南。本研究旨在比较接受术后放疗(PORT)或术后放化疗(POCRT)的伴有淋巴管侵犯的LSCC患者的生存率和毒性反应。研究结果可用于更合理地治疗这些患者。

患者与方法

388例符合条件的伴有淋巴管侵犯的LSCC患者纳入本回顾性研究。采用倾向评分匹配(PSM)方法(1:1)比较POCRT组和PORT组的生存率及治疗相关毒性反应。

结果

所有患者的5年总生存率(OS)、疾病特异性生存率(DSS)和无复发生存率(RFS)分别为48.7%、58.2%和56.0%。值得注意的是,PSM队列中POCRT组的RFS率显著高于PORT组(P = 0.040)。多因素分析显示,POCRT组的OS、DSS和RFS率均高于PORT组(分别为P = 0.049、0.024和0.011)。POCRT组患者出现的急性毒性反应比PORT组更多,如血液学毒性(25.0%对0.9%,P < 0.001)和黏膜炎(35.0%对19.1%,P = 0.002)。

结论

在没有针对伴有淋巴管侵犯的LSCC患者的理想治疗方案的情况下,本研究提出与PORT相比,POCRT是一种更优的治疗方式,因为POCRT与更高的RFS率相关。多因素分析中POCRT组的RFS、DFS和OS率也更高。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae98/7269631/824c8350ac71/CMAR-12-4063-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae98/7269631/824c8350ac71/CMAR-12-4063-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae98/7269631/824c8350ac71/CMAR-12-4063-g0001.jpg

相似文献

1
Postoperative Concurrent Chemoradiotherapy versus Postoperative Radiotherapy Alone for Larynx Squamous Cell Carcinoma Patients with Lymphovascular Invasion: A Propensity Score Matching Study.术后同步放化疗与单纯术后放疗治疗伴淋巴管浸润的喉鳞状细胞癌患者:一项倾向评分匹配研究
Cancer Manag Res. 2020 May 29;12:4063-4071. doi: 10.2147/CMAR.S250621. eCollection 2020.
2
Adding concurrent chemotherapy to postoperative radiotherapy improves locoregional control but Not overall survival in patients with salivary gland adenoid cystic carcinoma-a propensity score matched study.在涎腺腺样囊性癌患者中,术后放疗联合同期化疗可改善局部区域控制,但不能提高总生存率——一项倾向评分匹配研究
Radiat Oncol. 2016 Mar 22;11:47. doi: 10.1186/s13014-016-0617-7.
3
Postoperative Adjuvant Therapy Versus Surgery Alone for Stage IIB-III Esophageal Squamous Cell Carcinoma: A Phase III Randomized Controlled Trial.根治性手术与术后辅助放化疗治疗 IIB-III 期食管鳞癌的随机对照 III 期临床研究
Oncologist. 2021 Dec;26(12):e2151-e2160. doi: 10.1002/onco.13914. Epub 2021 Aug 19.
4
Role of postoperative chemoradiotherapy in head and neck cancer without positive margins or extracapsular extension: a propensity score-matching analysis.术后放化疗在无阳性切缘或囊外扩展的头颈部癌症中的作用:倾向评分匹配分析。
Radiat Oncol. 2022 Nov 13;17(1):180. doi: 10.1186/s13014-022-02152-w.
5
The Role of Adjuvant Chemoradiotherapy Over Radiotherapy After R0 Resection for Stage II-III Esophageal Squamous Cell Carcinoma.辅助放化疗在II-III期食管鳞状细胞癌R0切除术后相对于单纯放疗的作用
Cancer Manag Res. 2020 Mar 5;12:1631-1639. doi: 10.2147/CMAR.S232930. eCollection 2020.
6
Retromolar trigone squamous cell carcinoma: A population-based analysis of survival.磨牙后三角鳞状细胞癌:基于人群的生存分析。
Oral Oncol. 2022 Apr;127:105767. doi: 10.1016/j.oraloncology.2022.105767. Epub 2022 Feb 24.
7
A phase-II/III randomized controlled trial of adjuvant radiotherapy or concurrent chemoradiotherapy after surgery versus surgery alone in patients with stage-IIB/III esophageal squamous cell carcinoma.一项 II/III 期随机对照临床试验,比较了手术后辅助放疗或同期放化疗与单纯手术治疗 IIB/III 期食管鳞癌患者的效果。
BMC Cancer. 2020 Feb 18;20(1):130. doi: 10.1186/s12885-020-6592-2.
8
Postoperative chemoradiotherapy is superior to postoperative chemotherapy alone in squamous cell lung cancer patients with limited N2 lymph node metastasis.术后放化疗优于单纯术后化疗,适用于存在局限性 N2 淋巴结转移的鳞状细胞肺癌患者。
BMC Cancer. 2019 Oct 30;19(1):1023. doi: 10.1186/s12885-019-6141-z.
9
Platinum-based adjuvant chemoradiotherapy versus adjuvant radiotherapy in patients with head and neck adenoid cystic carcinoma.头颈部腺样囊性癌患者的铂类辅助放化疗与辅助放疗比较。
J Cancer Res Clin Oncol. 2024 Apr 16;150(4):195. doi: 10.1007/s00432-024-05719-0.
10
Comparison of efficacy for postoperative chemotherapy and concurrent radiochemotherapy in patients with IIIA-pN2 non-small cell lung cancer: an early closed randomized controlled trial.IIIA-pN2期非小细胞肺癌患者术后化疗与同步放化疗疗效比较:一项提前终止的随机对照试验
Radiother Oncol. 2014 Jan;110(1):120-5. doi: 10.1016/j.radonc.2013.10.008. Epub 2013 Oct 31.

本文引用的文献

1
Prognostic implications of human papillomavirus status and p16 expression in laryngeal squamous cell carcinoma.人乳头瘤病毒状态和 p16 表达对喉鳞状细胞癌的预后意义。
Head Neck. 2019 Dec;41(12):4151-4163. doi: 10.1002/hed.25961. Epub 2019 Sep 30.
2
Prognostic value of lymphovascular invasion of the primary tumor in hypopharyngeal carcinoma after total laryngopharyngectomy.下咽癌全喉咽切除术后原发肿瘤淋巴管侵犯的预后价值
Head Neck. 2017 Aug;39(8):1535-1543. doi: 10.1002/hed.24705. Epub 2017 Jun 5.
3
Cancer statistics in China, 2015.
《中国癌症统计数据 2015》
CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32. doi: 10.3322/caac.21338. Epub 2016 Jan 25.
4
Importance of lymphovascular invasion and invasive front on survival in floor of mouth cancer.淋巴管浸润和浸润前沿对口腔底癌生存的重要性。
Head Neck. 2016 Apr;38 Suppl 1:E1528-34. doi: 10.1002/hed.24273. Epub 2015 Nov 25.
5
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.全球癌症发病与死亡:GLOBOCAN 2012 数据源、方法与主要模式。
Int J Cancer. 2015 Mar 1;136(5):E359-86. doi: 10.1002/ijc.29210. Epub 2014 Oct 9.
6
Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck.RTOG 9501/Intergroup 三期临床试验的长期随访:头颈部高危鳞状细胞癌术后同期放化疗。
Int J Radiat Oncol Biol Phys. 2012 Dec 1;84(5):1198-205. doi: 10.1016/j.ijrobp.2012.05.008. Epub 2012 Jun 30.
7
Comparison of the Adult Comorbidity Evaluation 27 and the Charlson Comorbidity indices in patients with laryngeal squamous cell carcinoma.喉鳞状细胞癌患者中成人共病评估27指数与查尔森共病指数的比较。
J Laryngol Otol. 2012 May;126(5):516-24. doi: 10.1017/S0022215112000254. Epub 2012 Mar 26.
8
Clinical significance of lymphatic and blood vessel invasion in oral tongue squamous cell carcinomas.舌鳞癌中淋巴管和血管侵犯的临床意义。
Oral Oncol. 2012 Apr;48(4):320-4. doi: 10.1016/j.oraloncology.2011.11.014. Epub 2011 Dec 16.
9
Global cancer statistics.全球癌症统计数据。
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90. doi: 10.3322/caac.20107. Epub 2011 Feb 4.
10
Staging and survival analysis for nonsquamous cell carcinomas of the larynx.喉非鳞状细胞癌的分期及生存分析
Laryngoscope. 2008 Jun;118(6):1003-13. doi: 10.1097/MLG.0b013e3181671b3d.